ID
35346
Beskrivning
Study ID: 111364 Clinical Study ID: 111364 Study Title: A 28-Day, Polysomnographic and subjective assessment of Vestipitant (15mg/day) for the treatment of Primary Insomnia in adult Outpatients Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00992160 Clinicaltrials.gov Links: https://clinicaltrials.gov/ct2/show/NCT00992160 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Vestipitant, Placebo Trade Name: N/A Study Indication: Primary Insomnia, Sleep Disorders The purpose of this form is to record the subjects current medical conditions and should be filled out at visit 1 and visit 2.
Länk
https://clinicaltrials.gov/ct2/show/NCT00992160
Nyckelord
Versioner (3)
- 2019-02-23 2019-02-23 -
- 2019-03-01 2019-03-01 -
- 2019-11-10 2019-11-10 -
Rättsinnehavare
GlaxoSmithKline
Uppladdad den
1 mars 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Polysomnographic Assessment of Vestipitant for the Treatment of Primary Insomnia NCT00992160
Medical Conditions
- StudyEvent: ODM
Beskrivning
Medical Conditions
Alias
- UMLS CUI-1
- C0262926
Beskrivning
Check only one response for each MedDRA System Organ Class
Datatyp
integer
Alias
- UMLS CUI [1]
- C2347091
Beskrivning
Current
Datatyp
boolean
Alias
- UMLS CUI [1]
- C0521116
Beskrivning
Past
Datatyp
boolean
Alias
- UMLS CUI [1]
- C1444637
Beskrivning
No Medical History
Datatyp
boolean
Alias
- UMLS CUI [1]
- C0262926
Beskrivning
Not Assessed
Datatyp
boolean
Alias
- UMLS CUI [1]
- C3846720
Beskrivning
No Medical Condition
Datatyp
boolean
Alias
- UMLS CUI [1]
- C1699700
Similar models
Medical Conditions
- StudyEvent: ODM
C2985720 (UMLS CUI [1,2])